DE69635496T2 - Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen - Google Patents

Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen Download PDF

Info

Publication number
DE69635496T2
DE69635496T2 DE69635496T DE69635496T DE69635496T2 DE 69635496 T2 DE69635496 T2 DE 69635496T2 DE 69635496 T DE69635496 T DE 69635496T DE 69635496 T DE69635496 T DE 69635496T DE 69635496 T2 DE69635496 T2 DE 69635496T2
Authority
DE
Germany
Prior art keywords
toxigenic
difficile
strain
strains
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635496T
Other languages
German (de)
English (en)
Other versions
DE69635496D1 (de
Inventor
Dale N Gerding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gerding Dale N Chicago
Original Assignee
Gerding Dale N Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerding Dale N Chicago filed Critical Gerding Dale N Chicago
Application granted granted Critical
Publication of DE69635496D1 publication Critical patent/DE69635496D1/de
Publication of DE69635496T2 publication Critical patent/DE69635496T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69635496T 1995-09-15 1996-09-13 Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen Expired - Lifetime DE69635496T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US384795P 1995-09-15 1995-09-15
US3847P 1995-09-15
PCT/US1996/014868 WO1997009886A1 (fr) 1995-09-15 1996-09-13 Procedes et compositions pour prevenir et traiter les maladies associees a clostridium difficile

Publications (2)

Publication Number Publication Date
DE69635496D1 DE69635496D1 (de) 2005-12-29
DE69635496T2 true DE69635496T2 (de) 2006-07-27

Family

ID=21707876

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635496T Expired - Lifetime DE69635496T2 (de) 1995-09-15 1996-09-13 Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen

Country Status (8)

Country Link
US (1) US6635260B1 (fr)
EP (1) EP0952773B1 (fr)
AT (1) ATE310391T1 (fr)
AU (1) AU7362096A (fr)
CA (1) CA2232001C (fr)
DE (1) DE69635496T2 (fr)
ES (1) ES2248822T3 (fr)
WO (1) WO1997009886A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
CN101500581B (zh) * 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
US20130224164A1 (en) * 2010-09-10 2013-08-29 Viropharma Incorporated Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use
DK3549949T5 (da) 2011-04-22 2024-09-02 Wyeth Llc Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil
ES2792106T3 (es) * 2012-05-18 2020-11-10 Genome Res Ltd Métodos y grupos
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102617655B1 (ko) 2012-11-23 2023-12-27 세레스 테라퓨틱스, 인코포레이티드 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
EP2951283A4 (fr) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions et procédés
KR20230110367A (ko) 2013-02-04 2023-07-21 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
EP2967077A4 (fr) 2013-03-15 2016-09-14 Seres Therapeutics Inc Compositions microbiennes et procédés associés basés sur un réseau
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP6330032B2 (ja) 2013-06-05 2018-05-23 レビオティクス インコーポレイテッドＲｅｂｉｏｔｉｘ，Ｉｎｃ． 微生物叢回復療法組成物を製造、処理、および梱包するための方法
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (fr) 2013-12-16 2015-06-25 Seres Health, Inc. Compositions bactériennes et leurs méthodes d'utilisation pour traiter des troubles du système immunitaire
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
KR102066242B1 (ko) 2015-06-09 2020-01-14 리바이오틱스, 인코퍼레이티드 미생물상 복원 치료(mrt) 조성물 및 제조 방법
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
KR102554351B1 (ko) 2016-06-14 2023-07-13 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
HUE052258T2 (hu) * 2017-06-14 2021-04-28 4D Pharma Res Ltd Megasphaera nemzetségbe tartozó baktériumtörzset tartalmazó készítmény, és alkalmazása
KR102680943B1 (ko) 2017-08-14 2024-07-03 세레스 테라퓨틱스, 인코포레이티드 담즙정체성 질환 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
EP0952773A4 (fr) 2001-05-16
EP0952773B1 (fr) 2005-11-23
CA2232001A1 (fr) 1997-03-20
AU7362096A (en) 1997-04-01
CA2232001C (fr) 2002-12-10
ATE310391T1 (de) 2005-12-15
ES2248822T3 (es) 2006-03-16
WO1997009886A1 (fr) 1997-03-20
EP0952773A1 (fr) 1999-11-03
US6635260B1 (en) 2003-10-21
DE69635496D1 (de) 2005-12-29

Similar Documents

Publication Publication Date Title
DE69635496T2 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
Preac-Mursic et al. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi
DE69122298T2 (de) Behandlung von Clostridium difficile Diarrhöe und pseudomembraner Dickdarmentzündung
DE69930944T2 (de) Bacillus coagulans-zusammensetzung und deren verwendung
Swanson et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile
Russell et al. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia.
DE69919196T2 (de) Verfahren zum screening von antibakteriellen mitteln
RU2751509C1 (ru) Способы лечения и предотвращения инфекции с. difficile
DE69629691T2 (de) Verfahren zur kontrolle von antibiotikaresistenten grampositiven bakterien und behandlung von infektionen
DE69925371T2 (de) Impfstoff für geflügel
Kiser A perspective on the use of antibiotics in animal feeds
DE69432929T2 (de) Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
DE69829179T2 (de) Verfahren zur behandlung einer diarrhöischen krankheit und zur eliminierung besonderer bakterieller populationen im dickdarm
JP6134739B2 (ja) ビャクダン油およびクロストリジウム感染症に関連するその使用
DE69922017T2 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
Miller et al. Clinical efficacy of milbemycin oxime in the treatment of generalized demodicosis in adult dogs
DE69100314T2 (de) Behandlung von Clostridium difficile Diarrhöe und Pseudomembrankolitis.
Koga et al. In-vitro and in-vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori
DE602004010643T2 (de) E. coli vakzin zur protektion von geflügel gegen colibazillose
EP0655249B1 (fr) Moenomycin comme médicament pour le traitement des ulcères de l'estomac
DE4493997C2 (de) Neue abgeschwächte Pseudomonas-Aeruginosa-Stämme
DE69531186T2 (de) Antibordetella azellulärer Impfstoff
DE69230835T2 (de) Behandlung von protozoalen infekten mit bacitracin
CN106361777A (zh) 酪酸梭菌在制备预防或治疗孤独症制剂中的应用
Dineen The effect of alterations in intestinal flora on host resistance to systemic bacterial infection

Legal Events

Date Code Title Description
8364 No opposition during term of opposition